{"entity":{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","aka":[],"tldr":"Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.","summary":"Hervé Tilly (Rouen) was principal investigator and first author of POLARIX, which showed replacing vincristine with the CD79b ADC polatuzumab vedotin in R-CHOP reduces progression or death by 27% in previously untreated DLBCL. He has led LYSA trials for decades, including LNH03-6B in older patients, and chaired the ESMO DLBCL guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab"}],"tags":["lymphoma","adc","lysa"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc"],"targets":["cd20"],"drugs":[],"companies":["lysa"],"institutions":[],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":["paper-polarix-polatuzumab-rchp-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Centre Henri Becquerel and University of Rouen; LYSA","institutionId":"lysa","specialisms":["Diffuse large B-cell lymphoma","Antibody-drug conjugates","Cooperative-group trials","Lymphoma guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab"}],"papers":[{"title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115304"},{"title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv304"}]},"route":"/people/herve-tilly/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/"}],"trial":[{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/"}],"paper":[{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/"}]}}